Show simple item record

dc.contributor.authorButton, RW
dc.contributor.authorVincent, JH
dc.contributor.authorStrang, CJ
dc.contributor.authorLuo, Shouqing
dc.date.accessioned2017-01-04T14:32:13Z
dc.date.available2017-01-04T14:32:13Z
dc.date.issued2016-01-22
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10026.1/8192
dc.description.abstract

The PI-3 kinase (PI-3K)/mTOR pathway is critical for cell growth and proliferation. Strategies of antagonising this signaling have proven to be detrimental to cell survival. This observation, coupled with the fact many tumours show enhanced growth signaling, has caused dual inhibitors of PI-3K and mTOR to be implicated in cancer treatment, and have thus been studied across various tumour models. Since PI-3K (class-I)/mTOR pathway negatively regulates autophagy, dual inhibitors of PI-3K/mTOR are currently believed to be autophagy activators. However, our present data show that the dual PI-3K/mTOR inhibition (DKI) potently suppresses autophagic flux. We further confirm that inhibition of Vps34/PI3KC3, the class-III PI-3K, causes the blockade to autophagosome-lysosome fusion. Our data suggest that DKI induces cell death independently of apoptosis and necroptosis, whereas autophagy perturbation by DKI may contribute to cell death. Given that autophagy is critical in cellular homeostasis, our study not only clarifies the role of a dual PI-3K/mTOR inhibitor in autophagy, but also suggests that its autophagy inhibition needs to be considered if such an agent is used in cancer chemotherapy.

dc.format.extent5157-5175
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherImpact Journals, LLC
dc.subjectPI3KC3
dc.subjectapoptosis
dc.subjectautophagy
dc.subjectmTOR
dc.subjectnecroptosis
dc.subjectApoptosis
dc.subjectAutophagy
dc.subjectCell Death
dc.subjectCell Line, Tumor
dc.subjectHeLa Cells
dc.subjectHumans
dc.subjectNecrosis
dc.subjectPhosphatidylinositol 3-Kinases
dc.subjectPhosphoinositide-3 Kinase Inhibitors
dc.subjectSignal Transduction
dc.subjectTOR Serine-Threonine Kinases
dc.subjectTransfection
dc.titleDual PI-3 kinase/mTOR inhibition impairs autophagy flux and induces cell death independent of apoptosis and necroptosis
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26814436
plymouth.issue5
plymouth.volume7
plymouth.publication-statusPublished
plymouth.journalOncotarget
dc.identifier.doi10.18632/oncotarget.6986
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeUnited States
dcterms.dateAccepted2016-01-18
dc.identifier.eissn1949-2553
dc.rights.embargoperiodNo embargo
rioxxterms.versionofrecord10.18632/oncotarget.6986
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-01-22
rioxxterms.typeJournal Article/Review
plymouth.funderTackling autophagy and apoptosis for the potential therapy of Huntington's Disease::MRC


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV